Cyted: Revolutionizing Early Detection of Esophageal Cancer with Minimally Invasive Technology

Overview

Cyted is a health technology company focused on providing digital diagnostic infrastructure to revolutionize the early detection of cancer. Their core mission is to enable earlier, more accurate detection of esophageal disease, allowing clinicians to act sooner and patients to move forward with confidence. By utilizing artificial intelligence and novel biomarkers, Cyted aims to improve patient outcomes and reduce the burden on healthcare systems.

Benefits

Cyted offers several key advantages that address critical gaps in current cancer care. The company tackles the challenge of esophageal cancer, which is one of the most aggressive and fastest-growing cancers globally. A major issue is that fewer than 10% of patients with Barrett's Esophagus, the only known precursor to this cancer, receive a prior diagnosis. This leads to low survival rates, with only 1 in 5 people surviving their diagnosis.

The flagship product, EndoSign®, provides a minimally-invasive diagnostic tool that addresses these challenges. It is a non-endoscopic test used primarily in the Heartburn Health Check to monitor patients suffering from chronic heartburn and Barrett's Esophagus. The technology has been validated by an independent assessment conducted by IQVIA in partnership with NHS England. The study showed that the integration of capsule sponge technology reduced the demand for endoscopies in secondary care by 78%. This reduction has effectively alleviated resource pressure on delivering endoscopies, allowing patients waiting for procedures to be prioritized. Urgent cases can now be tested more quickly, reducing waiting lists and decreasing overall pressure on health systems.

In terms of cost, IQVIA calculated expected savings for the UK National Health Service of an estimated 421 pounds per patient. The introduction of the test at a national level is projected to generate cost savings of up to 33 million pounds over the course of five years for the NHS. Patient satisfaction levels were also high, with 82% of patients agreeing they were satisfied with their experience. Patients who had previously undergone endoscopies described the capsule sponge test as a preferable option to the current standard of care for diagnosing and monitoring Barrett's Esophagus.

Use Cases

EndoSign® is designed to be safe, accessible, and easy to administer. The technology has seen significant deployment across the UK and is expanding globally. Currently, over 60 hospitals and 15 GP-based clinics across England, Scotland, and Wales offer EndoSign® testing. The company has recently achieved College of American Pathologists accreditation for its US laboratory and launched the EndoSign® Capsule Sponge Test in high street pharmacies, further increasing accessibility.

The primary use case involves patients suffering from chronic heartburn and those diagnosed with Barrett's Esophagus. The process is simple: patients swallow a capsule containing a sponge that collects cells from the entire esophagus. The cell collection process takes less than ten minutes. The collected cells are then analyzed using advanced molecular diagnostics to detect abnormalities associated with esophageal cancer risk. This approach bridges the gap between early detection and clinical intervention, offering a scalable solution to one of the most pressing challenges in oncology.

Pricing

Pricing details for Cyted's EndoSign® test are not publicly disclosed in the available information. The company reports significant cost savings for healthcare systems, such as an estimated 421 pounds per patient for the NHS, but specific consumer or provider pricing is not mentioned.

Vibes

Public reception to Cyted's technology has been very positive. An independent assessment involving collaboration with NHS teams, Medtronic, Cancer Alliances, Cambridge University, and ENDOPREM yielded significant results. The study validated the efficacy of the technology and highlighted its ability to reduce diagnostic backlogs. Patient feedback indicates a strong preference for the capsule sponge test over traditional endoscopies. The high satisfaction rate of 82% suggests that the patient experience is a major strength of the product. Investors have also shown confidence, with Cyted securing a total funding of 84.51 million dollars as of recent data.

Additional Information

Cyted continues to expand its footprint and regulatory approvals to support global adoption. The company received 510(k) FDA clearance for its EndoSign® technology, facilitating its use in the United States. To drive growth in the US market, the company recently appointed Thomas West as Board Chair and Robert Epstein as Non-Executive Director. These strategic moves reflect the company's commitment to scaling its digital diagnostic infrastructure and improving access to early cancer detection worldwide.